Discontinued — last reported Q2 '23
Year-over-year, this metric grew by 79.2%, from $42.30M to $75.80M.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $21.10M | $9.20M | $9.10M | $6.10M | $6.10M | $27.20M | $18.20M | $12.20M | $12.10M | $18.20M | $15.20M | $0.00 | $42.30M | $45.50M | $54.60M | $0.00 | $75.80M |
| QoQ Change | — | — | — | — | -56.4% | -1.1% | -33.0% | +0.0% | +345.9% | -33.1% | -33.0% | -0.8% | +50.4% | -16.5% | -100.0% | — | +7.6% | +20.0% | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | -71.1% | +195.7% | +100.0% | +100.0% | +98.4% | -33.1% | -16.5% | -100.0% | +249.6% | +150.0% | +259.2% | — | +79.2% |